ANI Pharmaceuticals (NASDAQ:ANIP) Sets New 52-Week Low – Time to Sell?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)’s stock price hit a new 52-week low on Wednesday . The company traded as low as $69.96 and last traded at $70.4450, with a volume of 9889 shares. The stock had previously closed at $70.23.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $104.00 target price for the company. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $105.57.

ANI Pharmaceuticals Stock Up 0.3%

The company has a 50-day moving average of $78.12 and a two-hundred day moving average of $78.34. The company has a market capitalization of $1.62 billion, a P/E ratio of 15.12 and a beta of 0.45. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the company posted $1.80 earnings per share. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen Carey sold 2,850 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $72.80, for a total value of $207,480.00. Following the completion of the sale, the chief financial officer owned 171,843 shares in the company, valued at $12,510,170.40. This represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. This represents a 0.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 21,925 shares of company stock worth $1,728,385. 8.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. Penn Capital Management Company LLC increased its position in ANI Pharmaceuticals by 2,058.9% in the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock worth $10,858,000 after purchasing an additional 131,030 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares in the last quarter. CenterBook Partners LP purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $1,518,000. Jupiter Topco LLC bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $6,597,000. Finally, NFJ Investment Group LLC purchased a new position in ANI Pharmaceuticals in the second quarter worth about $2,766,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.